Patents by Inventor Dae Hyun HA

Dae Hyun HA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12219692
    Abstract: A printed circuit board includes a first substrate portion including a plurality of first insulating layers, a plurality of first wiring layers respectively disposed on the plurality of first insulating layers, and a plurality of first adhesive layers respectively disposed between the plurality of first insulating layers to respectively cover the plurality of first wiring layers; and a second substrate portion disposed on the first substrate portion, and including a plurality of second insulating layers, a plurality of second wiring layers respectively disposed on the plurality of second insulating layers, and a plurality of second adhesive layers respectively disposed between the plurality of second insulating layers to respectively cover the plurality of second wiring layers.
    Type: Grant
    Filed: November 22, 2023
    Date of Patent: February 4, 2025
    Assignee: SAMSUNG ELECTRO-MECHANICS CO., LTD.
    Inventors: Dae Jung Byun, Jung Soo Kim, Sang Hyun Sim, Chang Min Ha, Tae Hong Min, Jin Won Lee
  • Publication number: 20220127578
    Abstract: A method for producing exosomes is provided. The method includes culturing animal cells in a medium containing TNF-? and interferon-?. This method is possible not only to increase production of exosomes to be isolated from a cell-derived conditioned medium, but also to exhibit an excellent effect of enhancing bioactivity of exosomes, such as increasing elastin synthesis of exosomes.
    Type: Application
    Filed: January 7, 2022
    Publication date: April 28, 2022
    Applicant: EXOCOBIO INC.
    Inventors: Byong Seung CHO, Dae Hyun HA
  • Publication number: 20210395694
    Abstract: A method for promoting production of exosomes and/or extracellular vesicles is provided. The method includes culturing animal cells in a medium containing ascorbic acid, an analogue thereof, or a derivative thereof. The method is able to enhance the productivity of exosomes and/or extracellular vesicles secreted or released per cell or cell-derived conditioned medium.
    Type: Application
    Filed: September 2, 2021
    Publication date: December 23, 2021
    Applicant: ExoCoBio Inc.
    Inventors: Byong Seung CHO, Dae Hyun HA
  • Patent number: 10610514
    Abstract: The present invention relates to a composition including an inhibitor against the function of an Mi-2/NuRD chromatin remodeling complex for inhibiting metastasis and preventing and treating cancer diseases, and more particularly, the composition may inhibit the MBD2-p66? (GATAD2A) interaction by means of the Mi-2/NuRD CRC function inhibitor, and thus is expected to be effectively used as a composition capable of inhibiting metastasis and preventing and treating cancer diseases.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: April 7, 2020
    Assignees: Industry-University Cooperation Foundation Hanyang University, University of South Florida
    Inventors: Chul Geun Kim, Min Young Kim, Young Su Lim, Dae Hyun Ha, Young Yiul Lee, Buom Yong Ryu, Vladimir Uversky, Insung Na, Yu Chen, Arjan van der Vaart
  • Patent number: 10611797
    Abstract: A peptide binding to transcription factor CP2c, having an activity of preventing and treating cancer and represented by SEQ ID NO: 1: Asn-Tyr-Pro-Gln-Arg-Pro, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient are disclosed. When cancer cells are treated with the peptide and the pharmaceutical composition containing the same, the peptide can specifically bind to CP2c by passing, with very high stability, through the cell membrane and can inhibit the DNA binding ability of CP2c, thereby disturbing CP2c-mediated cancer cell-specific transcriptional activity through the inhibition of CP2c activity. Thus, the peptide and pharmaceutical composition containing the same can be effectively used for specifically treating only cancer cells and can be utilized for cancer prevention and as a dietary supplement additive therefor.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: April 7, 2020
    Assignee: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
    Inventors: Chul Geun Kim, Min Young Kim, Chan Gil Kim, Ho Chul Kang, Ji Hyung Chae, Su Jae Lee, Eun Jung Baek, Chae Ok Yun, Jin Won Lee, Young Su Lim, Je Min Choi, Dae Hyun Ha, Hyung Sik Won, Seung Han Son
  • Publication number: 20180086788
    Abstract: The present invention relates to a peptide having an anticancer activity, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient and, more specifically, to a peptide binding to transcription factor CP2c, having an activity of preventing and treating cancer and represented by SEQ ID NO: 1, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient.
    Type: Application
    Filed: March 29, 2016
    Publication date: March 29, 2018
    Inventors: Chul Geun KIM, Min Young KIM, Chan Gil KIM, Ho Chul KANG, Ji Hyung CHAE, Su Jae LEE, Eun Jung BAEK, Chae Ok YUN, Jin Won LEE, Young Su LIM, Je Min CHOI, Dae Hyun HA, Hyung Sik WON, Seung Han SON